nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—P-Glycoprotein Inhibitors—Crizotinib—lung cancer	0.329	1	CiPCiCtD
Everolimus—kidney cancer—lung cancer	0.286	1	CtDrD
Everolimus—MTOR—lung cancer	0.207	1	CbGaD
Everolimus—CYP3A4—Topotecan—lung cancer	0.00711	0.142	CbGbCtD
Everolimus—CYP3A4—Gefitinib—lung cancer	0.0065	0.13	CbGbCtD
Everolimus—CYP3A4—Teniposide—lung cancer	0.0063	0.126	CbGbCtD
Everolimus—CYP3A4—Vinorelbine—lung cancer	0.00501	0.1	CbGbCtD
Everolimus—CYP3A4—Crizotinib—lung cancer	0.00398	0.0796	CbGbCtD
Everolimus—CYP3A4—Erlotinib—lung cancer	0.00384	0.0768	CbGbCtD
Everolimus—CYP3A4—Paclitaxel—lung cancer	0.00352	0.0703	CbGbCtD
Everolimus—CYP3A4—Irinotecan—lung cancer	0.00347	0.0694	CbGbCtD
Everolimus—CYP3A4—Vinblastine—lung cancer	0.00309	0.0617	CbGbCtD
Everolimus—CYP3A4—Etoposide—lung cancer	0.00278	0.0556	CbGbCtD
Everolimus—CYP3A4—Docetaxel—lung cancer	0.00254	0.0508	CbGbCtD
Everolimus—CYP3A4—Doxorubicin—lung cancer	0.0019	0.0379	CbGbCtD
Everolimus—MTOR—mammary gland—lung cancer	0.0012	0.134	CbGeAlD
Everolimus—FKBP1A—mammary gland—lung cancer	0.00108	0.121	CbGeAlD
Everolimus—MTOR—respiratory system—lung cancer	0.000801	0.0895	CbGeAlD
Everolimus—FKBP1A—respiratory system—lung cancer	0.00072	0.0805	CbGeAlD
Everolimus—MTOR—epithelium—lung cancer	0.000669	0.0748	CbGeAlD
Everolimus—FKBP1A—epithelium—lung cancer	0.000602	0.0672	CbGeAlD
Everolimus—Pimecrolimus—MTOR—lung cancer	0.000593	0.304	CrCbGaD
Everolimus—FKBP1A—bronchus—lung cancer	0.000593	0.0662	CbGeAlD
Everolimus—FKBP1A—trachea—lung cancer	0.000532	0.0595	CbGeAlD
Everolimus—FKBP1A—cardiac atrium—lung cancer	0.0005	0.0559	CbGeAlD
Everolimus—MTOR—bone marrow—lung cancer	0.000469	0.0524	CbGeAlD
Everolimus—MTOR—lung—lung cancer	0.000425	0.0475	CbGeAlD
Everolimus—FKBP1A—bone marrow—lung cancer	0.000422	0.0472	CbGeAlD
Everolimus—Temsirolimus—MTOR—lung cancer	0.000401	0.205	CrCbGaD
Everolimus—FKBP1A—lung—lung cancer	0.000382	0.0427	CbGeAlD
Everolimus—Sirolimus—MTOR—lung cancer	0.000353	0.181	CrCbGaD
Everolimus—Tacrolimus—MTOR—lung cancer	0.000353	0.181	CrCbGaD
Everolimus—MTOR—lymph node—lung cancer	0.000291	0.0325	CbGeAlD
Everolimus—FKBP1A—lymph node—lung cancer	0.000262	0.0292	CbGeAlD
Everolimus—Temsirolimus—ABCB1—lung cancer	6.89e-05	0.0353	CrCbGaD
Everolimus—Tacrolimus—ALB—lung cancer	6.36e-05	0.0325	CrCbGaD
Everolimus—Tacrolimus—ABCB1—lung cancer	6.07e-05	0.031	CrCbGaD
Everolimus—Sirolimus—ABCB1—lung cancer	6.07e-05	0.031	CrCbGaD
Everolimus—Pain—Etoposide—lung cancer	1.38e-05	0.000194	CcSEcCtD
Everolimus—Constipation—Etoposide—lung cancer	1.38e-05	0.000194	CcSEcCtD
Everolimus—Dysuria—Doxorubicin—lung cancer	1.37e-05	0.000193	CcSEcCtD
Everolimus—Neutropenia—Doxorubicin—lung cancer	1.37e-05	0.000193	CcSEcCtD
Everolimus—Decreased appetite—Paclitaxel—lung cancer	1.37e-05	0.000193	CcSEcCtD
Everolimus—Dry mouth—Docetaxel—lung cancer	1.36e-05	0.000192	CcSEcCtD
Everolimus—Upper respiratory tract infection—Doxorubicin—lung cancer	1.36e-05	0.000192	CcSEcCtD
Everolimus—Haemoglobin—Methotrexate—lung cancer	1.36e-05	0.000192	CcSEcCtD
Everolimus—Gastrointestinal disorder—Paclitaxel—lung cancer	1.36e-05	0.000192	CcSEcCtD
Everolimus—Fatigue—Paclitaxel—lung cancer	1.36e-05	0.000191	CcSEcCtD
Everolimus—Hepatitis—Methotrexate—lung cancer	1.36e-05	0.000191	CcSEcCtD
Everolimus—Haemorrhage—Methotrexate—lung cancer	1.36e-05	0.000191	CcSEcCtD
Everolimus—Pollakiuria—Doxorubicin—lung cancer	1.36e-05	0.000191	CcSEcCtD
Everolimus—Asthenia—Gemcitabine—lung cancer	1.35e-05	0.00019	CcSEcCtD
Everolimus—Pain—Paclitaxel—lung cancer	1.35e-05	0.00019	CcSEcCtD
Everolimus—Constipation—Paclitaxel—lung cancer	1.35e-05	0.00019	CcSEcCtD
Everolimus—Pharyngitis—Methotrexate—lung cancer	1.35e-05	0.000189	CcSEcCtD
Everolimus—Urinary tract disorder—Methotrexate—lung cancer	1.34e-05	0.000189	CcSEcCtD
Everolimus—Oedema—Docetaxel—lung cancer	1.34e-05	0.000188	CcSEcCtD
Everolimus—Pruritus—Gemcitabine—lung cancer	1.33e-05	0.000188	CcSEcCtD
Everolimus—Urethral disorder—Methotrexate—lung cancer	1.33e-05	0.000187	CcSEcCtD
Everolimus—Infection—Docetaxel—lung cancer	1.33e-05	0.000187	CcSEcCtD
Everolimus—Weight decreased—Doxorubicin—lung cancer	1.33e-05	0.000187	CcSEcCtD
Everolimus—Feeling abnormal—Etoposide—lung cancer	1.33e-05	0.000187	CcSEcCtD
Everolimus—Hyperglycaemia—Doxorubicin—lung cancer	1.32e-05	0.000186	CcSEcCtD
Everolimus—Diarrhoea—Irinotecan—lung cancer	1.32e-05	0.000186	CcSEcCtD
Everolimus—Pneumonia—Doxorubicin—lung cancer	1.32e-05	0.000185	CcSEcCtD
Everolimus—Gastrointestinal pain—Etoposide—lung cancer	1.32e-05	0.000185	CcSEcCtD
Everolimus—Shock—Docetaxel—lung cancer	1.31e-05	0.000185	CcSEcCtD
Everolimus—Nervous system disorder—Docetaxel—lung cancer	1.31e-05	0.000185	CcSEcCtD
Everolimus—Thrombocytopenia—Docetaxel—lung cancer	1.31e-05	0.000184	CcSEcCtD
Everolimus—Infestation NOS—Doxorubicin—lung cancer	1.31e-05	0.000184	CcSEcCtD
Everolimus—Infestation—Doxorubicin—lung cancer	1.31e-05	0.000184	CcSEcCtD
Everolimus—Tachycardia—Docetaxel—lung cancer	1.3e-05	0.000184	CcSEcCtD
Everolimus—Feeling abnormal—Paclitaxel—lung cancer	1.3e-05	0.000183	CcSEcCtD
Everolimus—Skin disorder—Docetaxel—lung cancer	1.3e-05	0.000183	CcSEcCtD
Everolimus—Hypersensitivity—Cisplatin—lung cancer	1.29e-05	0.000182	CcSEcCtD
Everolimus—Gastrointestinal pain—Paclitaxel—lung cancer	1.29e-05	0.000182	CcSEcCtD
Everolimus—Diarrhoea—Gemcitabine—lung cancer	1.29e-05	0.000181	CcSEcCtD
Everolimus—Renal failure—Doxorubicin—lung cancer	1.29e-05	0.000181	CcSEcCtD
Everolimus—Dizziness—Irinotecan—lung cancer	1.28e-05	0.00018	CcSEcCtD
Everolimus—Stomatitis—Doxorubicin—lung cancer	1.27e-05	0.000179	CcSEcCtD
Everolimus—Jaundice—Doxorubicin—lung cancer	1.27e-05	0.000179	CcSEcCtD
Everolimus—Anorexia—Docetaxel—lung cancer	1.27e-05	0.000179	CcSEcCtD
Everolimus—Abdominal pain—Etoposide—lung cancer	1.27e-05	0.000179	CcSEcCtD
Everolimus—Body temperature increased—Etoposide—lung cancer	1.27e-05	0.000179	CcSEcCtD
Everolimus—Urinary tract infection—Doxorubicin—lung cancer	1.27e-05	0.000179	CcSEcCtD
Everolimus—Conjunctivitis—Doxorubicin—lung cancer	1.27e-05	0.000179	CcSEcCtD
Everolimus—Eye disorder—Methotrexate—lung cancer	1.27e-05	0.000178	CcSEcCtD
Everolimus—Asthenia—Cisplatin—lung cancer	1.26e-05	0.000177	CcSEcCtD
Everolimus—Cardiac disorder—Methotrexate—lung cancer	1.26e-05	0.000177	CcSEcCtD
Everolimus—Hypotension—Docetaxel—lung cancer	1.25e-05	0.000176	CcSEcCtD
Everolimus—Haematuria—Doxorubicin—lung cancer	1.25e-05	0.000176	CcSEcCtD
Everolimus—Abdominal pain—Paclitaxel—lung cancer	1.25e-05	0.000176	CcSEcCtD
Everolimus—Body temperature increased—Paclitaxel—lung cancer	1.25e-05	0.000176	CcSEcCtD
Everolimus—Hepatobiliary disease—Doxorubicin—lung cancer	1.24e-05	0.000174	CcSEcCtD
Everolimus—Epistaxis—Doxorubicin—lung cancer	1.23e-05	0.000174	CcSEcCtD
Everolimus—Angiopathy—Methotrexate—lung cancer	1.23e-05	0.000173	CcSEcCtD
Everolimus—Vomiting—Irinotecan—lung cancer	1.23e-05	0.000173	CcSEcCtD
Everolimus—Sinusitis—Doxorubicin—lung cancer	1.23e-05	0.000173	CcSEcCtD
Everolimus—Immune system disorder—Methotrexate—lung cancer	1.22e-05	0.000172	CcSEcCtD
Everolimus—Mediastinal disorder—Methotrexate—lung cancer	1.22e-05	0.000172	CcSEcCtD
Everolimus—Rash—Irinotecan—lung cancer	1.22e-05	0.000172	CcSEcCtD
Everolimus—Dermatitis—Irinotecan—lung cancer	1.22e-05	0.000171	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Docetaxel—lung cancer	1.22e-05	0.000171	CcSEcCtD
Everolimus—Chills—Methotrexate—lung cancer	1.22e-05	0.000171	CcSEcCtD
Everolimus—Headache—Irinotecan—lung cancer	1.21e-05	0.000171	CcSEcCtD
Everolimus—Insomnia—Docetaxel—lung cancer	1.21e-05	0.00017	CcSEcCtD
Everolimus—Diarrhoea—Cisplatin—lung cancer	1.2e-05	0.000169	CcSEcCtD
Everolimus—Paraesthesia—Docetaxel—lung cancer	1.2e-05	0.000169	CcSEcCtD
Everolimus—Alopecia—Methotrexate—lung cancer	1.2e-05	0.000169	CcSEcCtD
Everolimus—Vomiting—Gemcitabine—lung cancer	1.2e-05	0.000169	CcSEcCtD
Everolimus—Dyspnoea—Docetaxel—lung cancer	1.19e-05	0.000168	CcSEcCtD
Everolimus—Somnolence—Docetaxel—lung cancer	1.19e-05	0.000167	CcSEcCtD
Everolimus—Mental disorder—Methotrexate—lung cancer	1.19e-05	0.000167	CcSEcCtD
Everolimus—Rash—Gemcitabine—lung cancer	1.19e-05	0.000167	CcSEcCtD
Everolimus—Dermatitis—Gemcitabine—lung cancer	1.19e-05	0.000167	CcSEcCtD
Everolimus—Hypersensitivity—Etoposide—lung cancer	1.18e-05	0.000167	CcSEcCtD
Everolimus—Erythema—Methotrexate—lung cancer	1.18e-05	0.000166	CcSEcCtD
Everolimus—Malnutrition—Methotrexate—lung cancer	1.18e-05	0.000166	CcSEcCtD
Everolimus—Haemoglobin—Doxorubicin—lung cancer	1.18e-05	0.000166	CcSEcCtD
Everolimus—Headache—Gemcitabine—lung cancer	1.18e-05	0.000166	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—lung cancer	1.18e-05	0.000166	CcSEcCtD
Everolimus—Dyspepsia—Docetaxel—lung cancer	1.18e-05	0.000166	CcSEcCtD
Everolimus—Hepatitis—Doxorubicin—lung cancer	1.17e-05	0.000165	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—lung cancer	1.17e-05	0.000165	CcSEcCtD
Everolimus—Hypoaesthesia—Doxorubicin—lung cancer	1.17e-05	0.000164	CcSEcCtD
Everolimus—Pharyngitis—Doxorubicin—lung cancer	1.17e-05	0.000164	CcSEcCtD
Everolimus—Decreased appetite—Docetaxel—lung cancer	1.16e-05	0.000164	CcSEcCtD
Everolimus—Hypersensitivity—Paclitaxel—lung cancer	1.16e-05	0.000164	CcSEcCtD
Everolimus—Urinary tract disorder—Doxorubicin—lung cancer	1.16e-05	0.000163	CcSEcCtD
Everolimus—Oedema peripheral—Doxorubicin—lung cancer	1.16e-05	0.000163	CcSEcCtD
Everolimus—Dysgeusia—Methotrexate—lung cancer	1.16e-05	0.000163	CcSEcCtD
Everolimus—Gastrointestinal disorder—Docetaxel—lung cancer	1.15e-05	0.000162	CcSEcCtD
Everolimus—Asthenia—Etoposide—lung cancer	1.15e-05	0.000162	CcSEcCtD
Everolimus—Connective tissue disorder—Doxorubicin—lung cancer	1.15e-05	0.000162	CcSEcCtD
Everolimus—Fatigue—Docetaxel—lung cancer	1.15e-05	0.000162	CcSEcCtD
Everolimus—Urethral disorder—Doxorubicin—lung cancer	1.15e-05	0.000162	CcSEcCtD
Everolimus—Nausea—Irinotecan—lung cancer	1.15e-05	0.000162	CcSEcCtD
Everolimus—Pain—Docetaxel—lung cancer	1.14e-05	0.000161	CcSEcCtD
Everolimus—Constipation—Docetaxel—lung cancer	1.14e-05	0.000161	CcSEcCtD
Everolimus—Back pain—Methotrexate—lung cancer	1.14e-05	0.000161	CcSEcCtD
Everolimus—Pruritus—Etoposide—lung cancer	1.14e-05	0.00016	CcSEcCtD
Everolimus—Asthenia—Paclitaxel—lung cancer	1.13e-05	0.000159	CcSEcCtD
Everolimus—Nausea—Gemcitabine—lung cancer	1.12e-05	0.000158	CcSEcCtD
Everolimus—Vomiting—Cisplatin—lung cancer	1.12e-05	0.000157	CcSEcCtD
Everolimus—Pruritus—Paclitaxel—lung cancer	1.12e-05	0.000157	CcSEcCtD
Everolimus—Vision blurred—Methotrexate—lung cancer	1.11e-05	0.000157	CcSEcCtD
Everolimus—Rash—Cisplatin—lung cancer	1.11e-05	0.000156	CcSEcCtD
Everolimus—Dermatitis—Cisplatin—lung cancer	1.11e-05	0.000156	CcSEcCtD
Everolimus—Feeling abnormal—Docetaxel—lung cancer	1.1e-05	0.000155	CcSEcCtD
Everolimus—Diarrhoea—Etoposide—lung cancer	1.1e-05	0.000155	CcSEcCtD
Everolimus—Eye disorder—Doxorubicin—lung cancer	1.1e-05	0.000154	CcSEcCtD
Everolimus—Ill-defined disorder—Methotrexate—lung cancer	1.1e-05	0.000154	CcSEcCtD
Everolimus—Gastrointestinal pain—Docetaxel—lung cancer	1.09e-05	0.000154	CcSEcCtD
Everolimus—Anaemia—Methotrexate—lung cancer	1.09e-05	0.000154	CcSEcCtD
Everolimus—Flushing—Doxorubicin—lung cancer	1.09e-05	0.000153	CcSEcCtD
Everolimus—Cardiac disorder—Doxorubicin—lung cancer	1.09e-05	0.000153	CcSEcCtD
Everolimus—Diarrhoea—Paclitaxel—lung cancer	1.08e-05	0.000152	CcSEcCtD
Everolimus—Angiopathy—Doxorubicin—lung cancer	1.07e-05	0.00015	CcSEcCtD
Everolimus—Malaise—Methotrexate—lung cancer	1.06e-05	0.00015	CcSEcCtD
Everolimus—Dizziness—Etoposide—lung cancer	1.06e-05	0.00015	CcSEcCtD
Everolimus—Immune system disorder—Doxorubicin—lung cancer	1.06e-05	0.000149	CcSEcCtD
Everolimus—Mediastinal disorder—Doxorubicin—lung cancer	1.06e-05	0.000149	CcSEcCtD
Everolimus—Abdominal pain—Docetaxel—lung cancer	1.06e-05	0.000149	CcSEcCtD
Everolimus—Body temperature increased—Docetaxel—lung cancer	1.06e-05	0.000149	CcSEcCtD
Everolimus—Leukopenia—Methotrexate—lung cancer	1.06e-05	0.000149	CcSEcCtD
Everolimus—Chills—Doxorubicin—lung cancer	1.05e-05	0.000148	CcSEcCtD
Everolimus—Dizziness—Paclitaxel—lung cancer	1.04e-05	0.000147	CcSEcCtD
Everolimus—Nausea—Cisplatin—lung cancer	1.04e-05	0.000147	CcSEcCtD
Everolimus—Alopecia—Doxorubicin—lung cancer	1.04e-05	0.000146	CcSEcCtD
Everolimus—Cough—Methotrexate—lung cancer	1.03e-05	0.000145	CcSEcCtD
Everolimus—Mental disorder—Doxorubicin—lung cancer	1.03e-05	0.000145	CcSEcCtD
Everolimus—Convulsion—Methotrexate—lung cancer	1.02e-05	0.000144	CcSEcCtD
Everolimus—Vomiting—Etoposide—lung cancer	1.02e-05	0.000144	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—lung cancer	1.02e-05	0.000144	CcSEcCtD
Everolimus—Erythema—Doxorubicin—lung cancer	1.02e-05	0.000144	CcSEcCtD
Everolimus—Rash—Etoposide—lung cancer	1.01e-05	0.000143	CcSEcCtD
Everolimus—Dermatitis—Etoposide—lung cancer	1.01e-05	0.000143	CcSEcCtD
Everolimus—Headache—Etoposide—lung cancer	1.01e-05	0.000142	CcSEcCtD
Everolimus—Flatulence—Doxorubicin—lung cancer	1.01e-05	0.000142	CcSEcCtD
Everolimus—Myalgia—Methotrexate—lung cancer	1e-05	0.000141	CcSEcCtD
Everolimus—Chest pain—Methotrexate—lung cancer	1e-05	0.000141	CcSEcCtD
Everolimus—Arthralgia—Methotrexate—lung cancer	1e-05	0.000141	CcSEcCtD
Everolimus—Vomiting—Paclitaxel—lung cancer	1e-05	0.000141	CcSEcCtD
Everolimus—Dysgeusia—Doxorubicin—lung cancer	1e-05	0.000141	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	9.98e-06	0.000141	CcSEcCtD
Everolimus—Rash—Paclitaxel—lung cancer	9.94e-06	0.00014	CcSEcCtD
Everolimus—Dermatitis—Paclitaxel—lung cancer	9.93e-06	0.00014	CcSEcCtD
Everolimus—Discomfort—Methotrexate—lung cancer	9.93e-06	0.00014	CcSEcCtD
Everolimus—Back pain—Doxorubicin—lung cancer	9.89e-06	0.000139	CcSEcCtD
Everolimus—Headache—Paclitaxel—lung cancer	9.88e-06	0.000139	CcSEcCtD
Everolimus—Hypersensitivity—Docetaxel—lung cancer	9.85e-06	0.000139	CcSEcCtD
Everolimus—Muscle spasms—Doxorubicin—lung cancer	9.83e-06	0.000138	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—lung cancer	9.63e-06	0.000136	CcSEcCtD
Everolimus—Asthenia—Docetaxel—lung cancer	9.59e-06	0.000135	CcSEcCtD
Everolimus—Infection—Methotrexate—lung cancer	9.57e-06	0.000135	CcSEcCtD
Everolimus—Nausea—Etoposide—lung cancer	9.55e-06	0.000135	CcSEcCtD
Everolimus—Ill-defined disorder—Doxorubicin—lung cancer	9.48e-06	0.000134	CcSEcCtD
Everolimus—Pruritus—Docetaxel—lung cancer	9.46e-06	0.000133	CcSEcCtD
Everolimus—Nervous system disorder—Methotrexate—lung cancer	9.45e-06	0.000133	CcSEcCtD
Everolimus—Anaemia—Doxorubicin—lung cancer	9.45e-06	0.000133	CcSEcCtD
Everolimus—Thrombocytopenia—Methotrexate—lung cancer	9.43e-06	0.000133	CcSEcCtD
Everolimus—Agitation—Doxorubicin—lung cancer	9.39e-06	0.000132	CcSEcCtD
Everolimus—Nausea—Paclitaxel—lung cancer	9.37e-06	0.000132	CcSEcCtD
Everolimus—Skin disorder—Methotrexate—lung cancer	9.36e-06	0.000132	CcSEcCtD
Everolimus—Hyperhidrosis—Methotrexate—lung cancer	9.31e-06	0.000131	CcSEcCtD
Everolimus—Malaise—Doxorubicin—lung cancer	9.22e-06	0.00013	CcSEcCtD
Everolimus—Anorexia—Methotrexate—lung cancer	9.18e-06	0.000129	CcSEcCtD
Everolimus—Syncope—Doxorubicin—lung cancer	9.17e-06	0.000129	CcSEcCtD
Everolimus—Leukopenia—Doxorubicin—lung cancer	9.15e-06	0.000129	CcSEcCtD
Everolimus—Diarrhoea—Docetaxel—lung cancer	9.14e-06	0.000129	CcSEcCtD
Everolimus—Palpitations—Doxorubicin—lung cancer	9.03e-06	0.000127	CcSEcCtD
Everolimus—Hypotension—Methotrexate—lung cancer	9e-06	0.000127	CcSEcCtD
Everolimus—Loss of consciousness—Doxorubicin—lung cancer	8.98e-06	0.000126	CcSEcCtD
Everolimus—Cough—Doxorubicin—lung cancer	8.92e-06	0.000126	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—lung cancer	8.86e-06	0.000125	CcSEcCtD
Everolimus—Dizziness—Docetaxel—lung cancer	8.84e-06	0.000124	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—lung cancer	8.82e-06	0.000124	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Methotrexate—lung cancer	8.78e-06	0.000124	CcSEcCtD
Everolimus—Insomnia—Methotrexate—lung cancer	8.71e-06	0.000123	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—lung cancer	8.7e-06	0.000123	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—lung cancer	8.7e-06	0.000123	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—lung cancer	8.7e-06	0.000123	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—lung cancer	8.67e-06	0.000122	CcSEcCtD
Everolimus—Paraesthesia—Methotrexate—lung cancer	8.65e-06	0.000122	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	8.64e-06	0.000122	CcSEcCtD
Everolimus—Discomfort—Doxorubicin—lung cancer	8.6e-06	0.000121	CcSEcCtD
Everolimus—Dyspnoea—Methotrexate—lung cancer	8.59e-06	0.000121	CcSEcCtD
Everolimus—Somnolence—Methotrexate—lung cancer	8.56e-06	0.000121	CcSEcCtD
Everolimus—Dry mouth—Doxorubicin—lung cancer	8.51e-06	0.00012	CcSEcCtD
Everolimus—Vomiting—Docetaxel—lung cancer	8.5e-06	0.00012	CcSEcCtD
Everolimus—Dyspepsia—Methotrexate—lung cancer	8.48e-06	0.000119	CcSEcCtD
Everolimus—Rash—Docetaxel—lung cancer	8.43e-06	0.000119	CcSEcCtD
Everolimus—Dermatitis—Docetaxel—lung cancer	8.42e-06	0.000119	CcSEcCtD
Everolimus—Decreased appetite—Methotrexate—lung cancer	8.37e-06	0.000118	CcSEcCtD
Everolimus—Headache—Docetaxel—lung cancer	8.37e-06	0.000118	CcSEcCtD
Everolimus—Oedema—Doxorubicin—lung cancer	8.34e-06	0.000117	CcSEcCtD
Everolimus—Gastrointestinal disorder—Methotrexate—lung cancer	8.32e-06	0.000117	CcSEcCtD
Everolimus—Fatigue—Methotrexate—lung cancer	8.31e-06	0.000117	CcSEcCtD
Everolimus—Infection—Doxorubicin—lung cancer	8.29e-06	0.000117	CcSEcCtD
Everolimus—Pain—Methotrexate—lung cancer	8.24e-06	0.000116	CcSEcCtD
Everolimus—Shock—Doxorubicin—lung cancer	8.21e-06	0.000116	CcSEcCtD
Everolimus—Nervous system disorder—Doxorubicin—lung cancer	8.18e-06	0.000115	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—lung cancer	8.17e-06	0.000115	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—lung cancer	8.14e-06	0.000115	CcSEcCtD
Everolimus—Skin disorder—Doxorubicin—lung cancer	8.1e-06	0.000114	CcSEcCtD
Everolimus—Hyperhidrosis—Doxorubicin—lung cancer	8.06e-06	0.000114	CcSEcCtD
Everolimus—Anorexia—Doxorubicin—lung cancer	7.95e-06	0.000112	CcSEcCtD
Everolimus—Nausea—Docetaxel—lung cancer	7.94e-06	0.000112	CcSEcCtD
Everolimus—Feeling abnormal—Methotrexate—lung cancer	7.94e-06	0.000112	CcSEcCtD
Everolimus—Gastrointestinal pain—Methotrexate—lung cancer	7.88e-06	0.000111	CcSEcCtD
Everolimus—Hypotension—Doxorubicin—lung cancer	7.79e-06	0.00011	CcSEcCtD
Everolimus—Abdominal pain—Methotrexate—lung cancer	7.62e-06	0.000107	CcSEcCtD
Everolimus—Body temperature increased—Methotrexate—lung cancer	7.62e-06	0.000107	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Doxorubicin—lung cancer	7.6e-06	0.000107	CcSEcCtD
Everolimus—Insomnia—Doxorubicin—lung cancer	7.54e-06	0.000106	CcSEcCtD
Everolimus—Paraesthesia—Doxorubicin—lung cancer	7.49e-06	0.000105	CcSEcCtD
Everolimus—Dyspnoea—Doxorubicin—lung cancer	7.44e-06	0.000105	CcSEcCtD
Everolimus—Somnolence—Doxorubicin—lung cancer	7.42e-06	0.000104	CcSEcCtD
Everolimus—Dyspepsia—Doxorubicin—lung cancer	7.34e-06	0.000103	CcSEcCtD
Everolimus—Decreased appetite—Doxorubicin—lung cancer	7.25e-06	0.000102	CcSEcCtD
Everolimus—Gastrointestinal disorder—Doxorubicin—lung cancer	7.2e-06	0.000101	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—lung cancer	7.19e-06	0.000101	CcSEcCtD
Everolimus—Constipation—Doxorubicin—lung cancer	7.13e-06	0.0001	CcSEcCtD
Everolimus—Pain—Doxorubicin—lung cancer	7.13e-06	0.0001	CcSEcCtD
Everolimus—Hypersensitivity—Methotrexate—lung cancer	7.1e-06	9.99e-05	CcSEcCtD
Everolimus—Asthenia—Methotrexate—lung cancer	6.91e-06	9.73e-05	CcSEcCtD
Everolimus—Feeling abnormal—Doxorubicin—lung cancer	6.87e-06	9.68e-05	CcSEcCtD
Everolimus—Gastrointestinal pain—Doxorubicin—lung cancer	6.82e-06	9.6e-05	CcSEcCtD
Everolimus—Pruritus—Methotrexate—lung cancer	6.82e-06	9.6e-05	CcSEcCtD
Everolimus—Abdominal pain—Doxorubicin—lung cancer	6.59e-06	9.28e-05	CcSEcCtD
Everolimus—Body temperature increased—Doxorubicin—lung cancer	6.59e-06	9.28e-05	CcSEcCtD
Everolimus—Diarrhoea—Methotrexate—lung cancer	6.59e-06	9.28e-05	CcSEcCtD
Everolimus—Dizziness—Methotrexate—lung cancer	6.37e-06	8.97e-05	CcSEcCtD
Everolimus—Hypersensitivity—Doxorubicin—lung cancer	6.15e-06	8.65e-05	CcSEcCtD
Everolimus—Vomiting—Methotrexate—lung cancer	6.13e-06	8.62e-05	CcSEcCtD
Everolimus—Rash—Methotrexate—lung cancer	6.07e-06	8.55e-05	CcSEcCtD
Everolimus—Dermatitis—Methotrexate—lung cancer	6.07e-06	8.54e-05	CcSEcCtD
Everolimus—Headache—Methotrexate—lung cancer	6.03e-06	8.5e-05	CcSEcCtD
Everolimus—Asthenia—Doxorubicin—lung cancer	5.98e-06	8.43e-05	CcSEcCtD
Everolimus—Pruritus—Doxorubicin—lung cancer	5.9e-06	8.31e-05	CcSEcCtD
Everolimus—Nausea—Methotrexate—lung cancer	5.72e-06	8.06e-05	CcSEcCtD
Everolimus—Diarrhoea—Doxorubicin—lung cancer	5.71e-06	8.04e-05	CcSEcCtD
Everolimus—FKBP1A—Disease—CD4—lung cancer	5.54e-06	0.000121	CbGpPWpGaD
Everolimus—MTOR—Disease—HES1—lung cancer	5.52e-06	0.00012	CbGpPWpGaD
Everolimus—Dizziness—Doxorubicin—lung cancer	5.52e-06	7.77e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—KDR—lung cancer	5.51e-06	0.00012	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—lung cancer	5.5e-06	0.00012	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—lung cancer	5.5e-06	0.00012	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB3—lung cancer	5.47e-06	0.000119	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FLT1—lung cancer	5.37e-06	0.000117	CbGpPWpGaD
Everolimus—Vomiting—Doxorubicin—lung cancer	5.3e-06	7.47e-05	CcSEcCtD
Everolimus—Rash—Doxorubicin—lung cancer	5.26e-06	7.41e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—APP—lung cancer	5.26e-06	0.000114	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH3—lung cancer	5.26e-06	0.000114	CbGpPWpGaD
Everolimus—Dermatitis—Doxorubicin—lung cancer	5.25e-06	7.4e-05	CcSEcCtD
Everolimus—Headache—Doxorubicin—lung cancer	5.23e-06	7.36e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—FGF9—lung cancer	5.21e-06	0.000113	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—JUN—lung cancer	5.19e-06	0.000113	CbGpPWpGaD
Everolimus—MTOR—Disease—ERCC2—lung cancer	5.16e-06	0.000112	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGFR1—lung cancer	5.09e-06	0.000111	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CG—lung cancer	5.07e-06	0.00011	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APC—lung cancer	5.07e-06	0.00011	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KIT—lung cancer	5.07e-06	0.00011	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—lung cancer	5.07e-06	0.00011	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ATP5H—lung cancer	5.05e-06	0.00011	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB3—lung cancer	5.05e-06	0.00011	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—POMC—lung cancer	5.04e-06	0.00011	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1A—lung cancer	5.03e-06	0.000109	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2L1—lung cancer	5.03e-06	0.000109	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PTEN—lung cancer	5.02e-06	0.000109	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGF—lung cancer	5.02e-06	0.000109	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUNB—lung cancer	4.98e-06	0.000108	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—lung cancer	4.95e-06	6.98e-05	CcSEcCtD
Everolimus—MTOR—Disease—TERT—lung cancer	4.84e-06	0.000105	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—POMC—lung cancer	4.83e-06	0.000105	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1A—lung cancer	4.83e-06	0.000105	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTEN—lung cancer	4.82e-06	0.000105	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1A—lung cancer	4.81e-06	0.000105	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTEN—lung cancer	4.8e-06	0.000104	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EP300—lung cancer	4.79e-06	0.000104	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—BRAF—lung cancer	4.77e-06	0.000104	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6R—lung cancer	4.71e-06	0.000102	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CREBBP—lung cancer	4.7e-06	0.000102	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR1—lung cancer	4.7e-06	0.000102	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—SRC—lung cancer	4.65e-06	0.000101	CbGpPWpGaD
Everolimus—MTOR—Disease—HIF1A—lung cancer	4.63e-06	0.000101	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EP300—lung cancer	4.58e-06	9.95e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STK11—lung cancer	4.52e-06	9.83e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLBD1—lung cancer	4.5e-06	9.8e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAP2K1—lung cancer	4.49e-06	9.77e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NRAS—lung cancer	4.48e-06	9.74e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—SRC—lung cancer	4.47e-06	9.72e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—APOA1—lung cancer	4.46e-06	9.71e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CD—lung cancer	4.46e-06	9.7e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SRC—lung cancer	4.45e-06	9.68e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—KIT—lung cancer	4.41e-06	9.6e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGF—lung cancer	4.36e-06	9.49e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FOXO3—lung cancer	4.36e-06	9.49e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NRAS—lung cancer	4.3e-06	9.35e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—lung cancer	4.29e-06	9.33e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK3—lung cancer	4.29e-06	9.32e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—lung cancer	4.28e-06	9.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HSD17B10—lung cancer	4.12e-06	8.96e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CASP8—lung cancer	4.11e-06	8.94e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAPK3—lung cancer	4.1e-06	8.92e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6R—lung cancer	4.1e-06	8.91e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CREBBP—lung cancer	4.09e-06	8.9e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AVP—lung cancer	4.09e-06	8.89e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—lung cancer	4.08e-06	8.87e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KIT—lung cancer	4.08e-06	8.86e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—APC—lung cancer	4.08e-06	8.86e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDH1—lung cancer	4.06e-06	8.83e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EGF—lung cancer	4.03e-06	8.76e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MDM2—lung cancer	4e-06	8.69e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—lung cancer	3.99e-06	8.67e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RAF1—lung cancer	3.98e-06	8.66e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—lung cancer	3.94e-06	8.57e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1R—lung cancer	3.93e-06	8.56e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—lung cancer	3.92e-06	8.52e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAP2K1—lung cancer	3.91e-06	8.49e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—lung cancer	3.9e-06	8.48e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CB—lung cancer	3.89e-06	8.46e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MTOR—lung cancer	3.89e-06	8.46e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CD—lung cancer	3.88e-06	8.44e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HES1—lung cancer	3.87e-06	8.41e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—lung cancer	3.85e-06	8.38e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—BRAF—lung cancer	3.83e-06	8.33e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CKB—lung cancer	3.83e-06	8.33e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6R—lung cancer	3.78e-06	8.23e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CREBBP—lung cancer	3.78e-06	8.22e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—lung cancer	3.74e-06	8.13e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—lung cancer	3.7e-06	8.05e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—lung cancer	3.68e-06	8.01e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAP2K1—lung cancer	3.61e-06	7.84e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM2—lung cancer	3.6e-06	7.83e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CNDP2—lung cancer	3.6e-06	7.83e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CD—lung cancer	3.58e-06	7.79e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—lung cancer	3.58e-06	7.78e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—lung cancer	3.57e-06	7.77e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—lung cancer	3.54e-06	7.7e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB3—lung cancer	3.53e-06	7.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTMR3—lung cancer	3.5e-06	7.62e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—lung cancer	3.48e-06	7.57e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MDM2—lung cancer	3.48e-06	7.56e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JUN—lung cancer	3.47e-06	7.55e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—RAF1—lung cancer	3.46e-06	7.53e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB2—lung cancer	3.43e-06	7.45e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PGAM1—lung cancer	3.41e-06	7.42e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—lung cancer	3.4e-06	7.39e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TERT—lung cancer	3.39e-06	7.37e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—lung cancer	3.38e-06	7.36e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CB—lung cancer	3.38e-06	7.36e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—lung cancer	3.38e-06	7.35e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—lung cancer	3.38e-06	7.34e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1A—lung cancer	3.37e-06	7.32e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—lung cancer	3.36e-06	7.31e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR1—lung cancer	3.29e-06	7.15e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—lung cancer	3.27e-06	7.12e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2A7—lung cancer	3.26e-06	7.08e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HIF1A—lung cancer	3.24e-06	7.04e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MDM2—lung cancer	3.21e-06	6.98e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EP300—lung cancer	3.2e-06	6.97e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—RAF1—lung cancer	3.2e-06	6.96e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SDC4—lung cancer	3.19e-06	6.93e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB2—lung cancer	3.16e-06	6.88e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—lung cancer	3.14e-06	6.84e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—lung cancer	3.13e-06	6.82e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—lung cancer	3.13e-06	6.81e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOA1—lung cancer	3.13e-06	6.8e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CB—lung cancer	3.12e-06	6.79e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—lung cancer	3.12e-06	6.78e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SRC—lung cancer	3.12e-06	6.78e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—lung cancer	3.11e-06	6.75e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KDR—lung cancer	3.1e-06	6.74e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—lung cancer	3.09e-06	6.73e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—lung cancer	3.03e-06	6.6e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—JUN—lung cancer	3.02e-06	6.57e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—lung cancer	3e-06	6.53e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—lung cancer	3e-06	6.52e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—lung cancer	3e-06	6.52e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1A—lung cancer	2.93e-06	6.37e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—lung cancer	2.92e-06	6.36e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTA3—lung cancer	2.9e-06	6.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—RRM1—lung cancer	2.9e-06	6.31e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—lung cancer	2.89e-06	6.29e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK3—lung cancer	2.87e-06	6.24e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APC—lung cancer	2.85e-06	6.21e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CG—lung cancer	2.85e-06	6.21e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KIT—lung cancer	2.85e-06	6.21e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGF—lung cancer	2.82e-06	6.13e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—lung cancer	2.79e-06	6.07e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—EP300—lung cancer	2.79e-06	6.06e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—lung cancer	2.78e-06	6.04e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—lung cancer	2.76e-06	6.01e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—lung cancer	2.73e-06	5.94e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—B4GALT5—lung cancer	2.73e-06	5.94e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—POMC—lung cancer	2.72e-06	5.91e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—SRC—lung cancer	2.71e-06	5.89e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1A—lung cancer	2.7e-06	5.88e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—lung cancer	2.7e-06	5.87e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BRAF—lung cancer	2.68e-06	5.83e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTA4—lung cancer	2.66e-06	5.77e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6R—lung cancer	2.65e-06	5.76e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CREBBP—lung cancer	2.65e-06	5.75e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—lung cancer	2.61e-06	5.68e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—lung cancer	2.61e-06	5.67e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTA2—lung cancer	2.59e-06	5.63e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—lung cancer	2.58e-06	5.61e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EP300—lung cancer	2.57e-06	5.6e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAP2K1—lung cancer	2.53e-06	5.49e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CD—lung cancer	2.51e-06	5.46e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—SRC—lung cancer	2.5e-06	5.44e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK3—lung cancer	2.5e-06	5.43e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTA1—lung cancer	2.5e-06	5.43e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCC3—lung cancer	2.47e-06	5.37e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—lung cancer	2.41e-06	5.25e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—lung cancer	2.41e-06	5.24e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKR1C1—lung cancer	2.39e-06	5.2e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—lung cancer	2.38e-06	5.17e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—lung cancer	2.37e-06	5.15e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UGT1A1—lung cancer	2.32e-06	5.05e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK3—lung cancer	2.31e-06	5.01e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—lung cancer	2.29e-06	4.99e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MDM2—lung cancer	2.25e-06	4.89e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—lung cancer	2.24e-06	4.88e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—lung cancer	2.24e-06	4.88e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RAF1—lung cancer	2.24e-06	4.87e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNG11—lung cancer	2.24e-06	4.87e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—lung cancer	2.22e-06	4.82e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—lung cancer	2.19e-06	4.77e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—lung cancer	2.19e-06	4.77e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CB—lung cancer	2.19e-06	4.76e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDOA—lung cancer	2.13e-06	4.63e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—lung cancer	2.1e-06	4.57e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—lung cancer	2.1e-06	4.56e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—lung cancer	2.07e-06	4.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NCOA3—lung cancer	2.07e-06	4.5e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—lung cancer	2.06e-06	4.48e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADCY1—lung cancer	2.01e-06	4.38e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCG2—lung cancer	2.01e-06	4.38e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—lung cancer	2.01e-06	4.37e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—lung cancer	2.01e-06	4.37e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO2—lung cancer	1.97e-06	4.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HPGDS—lung cancer	1.97e-06	4.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.96e-06	4.26e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—lung cancer	1.96e-06	4.26e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUN—lung cancer	1.95e-06	4.25e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—lung cancer	1.94e-06	4.21e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTT1—lung cancer	1.91e-06	4.16e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—lung cancer	1.91e-06	4.15e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—lung cancer	1.9e-06	4.14e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—lung cancer	1.9e-06	4.13e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1A—lung cancer	1.89e-06	4.12e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCLC—lung cancer	1.89e-06	4.11e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2A6—lung cancer	1.89e-06	4.11e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—lung cancer	1.89e-06	4.11e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—lung cancer	1.83e-06	3.97e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EP300—lung cancer	1.8e-06	3.92e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO1—lung cancer	1.79e-06	3.9e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—lung cancer	1.76e-06	3.83e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SRC—lung cancer	1.75e-06	3.81e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—lung cancer	1.71e-06	3.71e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—lung cancer	1.69e-06	3.68e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—lung cancer	1.69e-06	3.67e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—lung cancer	1.69e-06	3.67e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—lung cancer	1.68e-06	3.66e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK3—lung cancer	1.61e-06	3.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2E1—lung cancer	1.61e-06	3.5e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NQO1—lung cancer	1.59e-06	3.46e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—lung cancer	1.57e-06	3.41e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—lung cancer	1.56e-06	3.38e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—lung cancer	1.54e-06	3.34e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—lung cancer	1.45e-06	3.16e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—STK11—lung cancer	1.43e-06	3.12e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—lung cancer	1.33e-06	2.9e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTP1—lung cancer	1.33e-06	2.89e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAT—lung cancer	1.29e-06	2.81e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—lung cancer	1.29e-06	2.8e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCB1—lung cancer	1.26e-06	2.73e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMS—lung cancer	1.23e-06	2.68e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—lung cancer	1.23e-06	2.68e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—lung cancer	1.22e-06	2.65e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—lung cancer	1.18e-06	2.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP1A1—lung cancer	1.16e-06	2.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ERCC2—lung cancer	1.15e-06	2.49e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—lung cancer	1.09e-06	2.37e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA1—lung cancer	9.92e-07	2.16e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CG—lung cancer	9.05e-07	1.97e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—POMC—lung cancer	8.62e-07	1.87e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CREBBP—lung cancer	8.39e-07	1.83e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CD—lung cancer	7.96e-07	1.73e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—lung cancer	7.86e-07	1.71e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CB—lung cancer	6.94e-07	1.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—lung cancer	6.87e-07	1.49e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—lung cancer	5.99e-07	1.3e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—EP300—lung cancer	5.72e-07	1.24e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—lung cancer	4.23e-07	9.2e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—lung cancer	3.45e-07	7.51e-06	CbGpPWpGaD
